Astrazeneca

FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (47)Imfinzi approved in US for early bladder cancer
Preheader (145)Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer.
Typography
Arial
Colors
Text Analysis
Body Words125
Subject Words8
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px716 px
X-Spam Score-0.5
Preheader OptimizedNo
Timing
Day of WeekThursday
TimeOvernight

Imfinzi approved in US for early bladder cancer

Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer.
Imfinzi approved in US for early bladder cancer